- Home
- ELTX vs STKS Comparison
ELTX vs STKS Comparison
Compare ELTX & STKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELTX
- STKS
- Stock Information
- Founded
- ELTX 2011
- STKS 2004
- Country
- ELTX United States
- STKS United States
- Employees
- ELTX N/A
- STKS N/A
- Industry
- ELTX Biotechnology: Pharmaceutical Preparations
- STKS Restaurants
- Sector
- ELTX Health Care
- STKS Consumer Discretionary
- Exchange
- ELTX Nasdaq
- STKS Nasdaq
- Market Cap
- ELTX 121.7M
- STKS N/A
- IPO Year
- ELTX N/A
- STKS N/A
- Fundamental
- Price
- ELTX $5.57
- STKS $3.52
- Analyst Decision
- ELTX Strong Buy
- STKS Buy
- Analyst Count
- ELTX 2
- STKS 2
- Target Price
- ELTX $9.50
- STKS $4.25
- AVG Volume (30 Days)
- ELTX 34.1K
- STKS 67.5K
- Earning Date
- ELTX 05-19-2025
- STKS 05-07-2025
- Dividend Yield
- ELTX N/A
- STKS N/A
- EPS Growth
- ELTX N/A
- STKS N/A
- EPS
- ELTX N/A
- STKS N/A
- Revenue
- ELTX N/A
- STKS $799,478,000.00
- Revenue This Year
- ELTX N/A
- STKS $27.93
- Revenue Next Year
- ELTX N/A
- STKS $4.87
- P/E Ratio
- ELTX N/A
- STKS N/A
- Revenue Growth
- ELTX N/A
- STKS 138.50
- 52 Week Low
- ELTX $3.34
- STKS $2.37
- 52 Week High
- ELTX $11.45
- STKS $6.10
- Technical
- Relative Strength Index (RSI)
- ELTX 51.02
- STKS 69.59
- Support Level
- ELTX $4.85
- STKS $2.95
- Resistance Level
- ELTX $5.75
- STKS $3.14
- Average True Range (ATR)
- ELTX 0.49
- STKS 0.16
- MACD
- ELTX 0.14
- STKS 0.05
- Stochastic Oscillator
- ELTX 70.28
- STKS 96.82
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.